In the Media

Companies pair up to take Rett Syndrome program into clinic - July 20, 2017


News of Note—Trevena CMO exit; AMO deal; Kala IPO; AliveCor-Mayo pact - July 20, 2017


FDA Gives Fast Track Status to Potential Therapy for Congenital Myotonic Dystrophy - June 1, 2017


AMO Pharma receives FDA Fast Track Status - May 30, 2017

FDA Fast Tracks Muscular Dystrophy Drug backed by Woodford - May 30, 2017


AMO Pharma Addresses Rare Childhood Disease - May 22, 2017


Ranedis and AMO Partner to Develop HDAC Inhibitor for Rare Genetic Diseases - March 14, 2017


AMO Pharma and Ranedis target rare genetic diseases in RND-001 deal - March 14, 2017


Wayne-Based AMO Pharma Raises $25 Million - October 1, 2015


Neil Woodford’s Latest €25M UK Biotech pay-out is to AMO Pharma - October 1, 2015

Stay updated about AMO! Enter your information here to receive updates about AMO Pharma via email:

To unsubscribe from all AMO Pharma communications, please click here.